Addison ’s disease Drugs Market- Industry Analysis and Forecast

Addison’s Disease Drugs Market Size by Diagnosis, Treatment, End User, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2030

7.23%

CAGR (2024-2030)

2.42 USD Bn.

Forecast Market Size

311

Report Pages

152

Market Tables

Overview

Addison's disease Drugs Market is expected to reach US$ 3.95 Bn. at a CAGR of 7.23 % during the forecast period 2030. The rising prevalence of Addison's disease coupled with advancements in drug development targeting adrenal insufficiency are key factors propelling the growth of Addison's disease drugs market, expected to register a CAGR of 7.23% by 2030.

Addison's disease is a rare condition in which the two outer layers of cells in the adrenal glands (adrenal cortex) are unable to produce enough cortisol and aldosterone. Addison's disease drugs are medications used to treat people who have adrenal insufficiency. These medications assist in replenishing insufficient hormones generated by the adrenal glands. The Addison's Disease drugs market has been growing continuously as the condition's incidence has increased substantially all across the world as well as increasing advances in pharmaceutical research and development. The market is expected to grow significantly, as more effective and focused therapies are developed during the forecast period.

According to the MMR Addison's Disease drugs report, the Addison's Disease drugs market is expected to grow substantially as global knowledge and diagnosis of the ailment increase, providing attractive potential prospects for Addison's Disease drugs manufacturers throughout the forecast period. In addition, increased patient awareness, development and progress in therapies, and the emergence of modern healthcare organizations are all major factors driving the need for Addison's disease drugs. likewise, increased incidences of Addison's disease and an increase in research and development initiatives conducted by various pharmaceutical firms contribute to the growth of Addison's disease drugs market.
To know about the Research Methodology :- Request Free Sample Report

Addison’s Disease Drugs Market Dynamics:

Addison’s disease is a rare adrenal gland hormonal disorder which affects approximately less than 1 million people around the world. The growth of the Addison’s disease drugs market can attribute to various factors such as growing awareness about the disease and the available diagnosis for the same, reformulation of drugs, special drug designations and several reimbursement policies.

Further R&D is developing advanced treatments in which adrenocortical stem cells will be combined with immunomodulatory treatment resulting in the modification of the immune system.

Addison’s Disease Drugs Market Segment Analysis:

According to the studies, in the diagnosis segment of the market, blood tests are the prime source used for diagnosing the Addison’s disease. This is because blood tests correctly point out the levels of sodium, potassium, cortisol, and adrenocorticotropic hormone (ACTH) which are responsible for the production of adrenal hormones. Next in line is the ACTH Stimulation test as ACTH signals the adrenal to produce hormones and this test ensures that there is no secondary adrenal inefficiency.

Addison’s Disease Drugs Market Regional Analysis:

The Addison’s disease drug market in the US and other countries of North America is huge and is growing constantly. This attributes to the presence of well-developed healthcare infrastructure, awareness about the disease, and favorable reimbursement policies. Europe ranks second in Addison’s disease drug market due to the increase in the expenditure on the health sector. On contrary, the Middle East and Africa account for the least of the Addison’s disease drug market in the world.

Addison’s Disease Drugs Market Competitive Landscape:

The competitive landscape section in Addison’s Disease Drugs Market offers a deep dive into the profiles of the leading players operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the companies having a stronghold in the Addison’s Disease Drugs Market. In November 2013, Shire acquired shares of ViroPharma making both financially strong.

The objective of the report is to present a comprehensive analysis of the Global Addison’s Disease Market including all the stakeholders of the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Addison’s Disease Drugs Market dynamics, structure by analyzing the Market segments and projects the Global Addison’s Disease Drugs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Addison’s Disease Market make the report investor’s guide.

Addison’s Disease Drugs Market Scope :Inquire before buying

Addison’s Disease Drugs Market
Report Coverage	Details
Base Year:	2023	Forecast Period:	2024-2030
Historical Data:	2018 to 2023	Market Size in 2023:	US $ 2.42 Bn.
Forecast Period 2024 to 2030 CAGR:	7.23 %	Market Size in 2030:	US $ 3.95 Bn.
Segments Covered:	by Diagnosis	Laboratory Tests Image Testing
	by Treatment	Oral Corticosteroid Corticosteroid Injections
	by End User	Hospitals and Clinics Diagnostic Laboratories Other End Users

Addison's disease Drugs Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Major Addison's Disease Drugs Market Players

1. Bristol-Myers Squibb Company
2. Merck & Co. Inc.
3. Novartis AG
4. Pfizer Inc.
5. Takeda Pharmaceutical Company Ltd
6. Boehringer Ingelheim International GmbH
7. Shire
8. Tocris Bioscience
9. GlaxoSmithKline
10. Lupin Pharmaceuticals Inc.
11. Abbott Laboratories
12. Amgen Limited
13. Bayer AG
14. Biogen
15. Eli Lilly and Company
16. Diurnal
17. Bio-Techne
18. Switzer Life Science
19. Recipharm
20. ViroPharma

Frequently Asked Questions:

1. Which region has the largest share in Global Addison’s disease Drugs Market?
Ans: North America region held the highest share in 2023.

2. What is the growth rate of Global Addison’s disease Drugs Market?
Ans: The Global Addison’s disease Drugs Market is growing at a CAGR of 7.23 % during forecasting period 2024-2030.

3. What is scope of the Global Market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Bristol-Myers Squibb Company, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd, Boehringer Ingelheim International GmbH, Shire, Tocris Bioscience, GlaxoSmithKline, Lupin Pharmaceuticals Inc., Abbott Laboratories, Amgen Limited & Amgen Ireland Limited, Bayer AG, Biogen, Eli Lilly and Company, Diurnal, Switzer Life science Pvt. Ltd., ViroPharma, DuoCort Pharma AB.

5. What is the study period of this Market?
Ans: The Global Market is studied from 2023 to 2030.

Global Addison’s Disease Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Addison’s Disease Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Addison’s Disease Drugs Market Analysis and Forecast 6.1. Addison’s Disease Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Addison’s Disease Drugs Market Analysis and Forecast, By Diagnosis 7.1. Introduction and Definition 7.2. Key Findings 7.3. Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 7.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By Diagnosis 7.5. Addison’s Disease Drugs Market Analysis, By Diagnosis 7.6. Addison’s Disease Drugs Market Attractiveness Analysis, By Diagnosis 8. Global Addison’s Disease Drugs Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Addison’s Disease Drugs Market Value Share Analysis, By Treatment 8.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By Treatment 8.5. Addison’s Disease Drugs Market Analysis, By Treatment 8.6. Addison’s Disease Drugs Market Attractiveness Analysis, By Treatment 9. Global Addison’s Disease Drugs Market Analysis and Forecast, By End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Addison’s Disease Drugs Market Value Share Analysis, By End User 9.4. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, By End User 9.5. Addison’s Disease Drugs Market Analysis, By End User 9.6. Addison’s Disease Drugs Market Attractiveness Analysis, By End User 10. Global Addison’s Disease Drugs Market Analysis, by Region 10.1. Addison’s Disease Drugs Market Value Share Analysis, by Region 10.2. Addison’s Disease Drugs Market Size (US$ Bn) Forecast, by Region 10.3. Addison’s Disease Drugs Market Attractiveness Analysis, by Region 11. North America Addison’s Disease Drugs Market Analysis 11.1. Key Findings 11.2. North America Addison’s Disease Drugs Market Overview 11.3. North America Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 11.4. North America Addison’s Disease Drugs Market Forecast, By Diagnosis 11.4.1. Laboratory Tests 11.4.2. Image Tests 11.5. North America Addison’s Disease Drugs Market Value Share Analysis, By Treatment 11.6. North America Addison’s Disease Drugs Market Forecast, By Treatment 11.6.1. Oral Corticosteroid 11.6.2. Corticosteroid Injections 11.7. North America Addison’s Disease Drugs Market Value Share Analysis, By End User 11.8. North America Addison’s Disease Drugs Market Forecast, By End User 11.8.1. Hospitals and Clinics 11.8.2. Diagnostic Laboratories 11.8.3. Other End Users 11.9. North America Addison’s Disease Drugs Market Value Share Analysis, by Country 11.10. North America Addison’s Disease Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Addison’s Disease Drugs Market Analysis, by Country 11.12. U.S. Addison’s Disease Drugs Market Forecast, By Diagnosis 11.12.1. Laboratory Tests 11.12.2. Image Tests 11.13. U.S. Addison’s Disease Drugs Market Forecast, By Treatment 11.13.1. Oral Corticosteroid 11.13.2. Corticosteroid Injections 11.14. U.S. Addison’s Disease Drugs Market Forecast, By End User 11.14.1. Hospitals and Clinics 11.14.2. Diagnostic Laboratories 11.14.3. Other End Users 11.15. Canada Addison’s Disease Drugs Market Forecast, By Diagnosis 11.15.1. Laboratory Tests 11.15.2. Image Tests 11.16. Canada Addison’s Disease Drugs Market Forecast, By Treatment 11.16.1. Oral Corticosteroid 11.16.2. Corticosteroid Injections 11.17. Canada Addison’s Disease Drugs Market Forecast, By End User 11.17.1. Hospitals and Clinics 11.17.2. Diagnostic Laboratories 11.17.3. Other End Users 11.18. North America Addison’s Disease Drugs Market Attractiveness Analysis 11.18.1. By Diagnosis 11.18.2. By Treatment 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Addison’s Disease Drugs Market Analysis 12.1. Key Findings 12.2. Europe Addison’s Disease Drugs Market Overview 12.3. Europe Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 12.4. Europe Addison’s Disease Drugs Market Forecast, By Diagnosis 12.4.1. Laboratory Tests 12.4.2. Image Tests 12.5. Europe Addison’s Disease Drugs Market Value Share Analysis, By Treatment 12.6. Europe Addison’s Disease Drugs Market Forecast, By Treatment 12.6.1. Oral Corticosteroid 12.6.2. Corticosteroid Injections 12.7. Europe Addison’s Disease Drugs Market Value Share Analysis, By End User 12.8. Europe Addison’s Disease Drugs Market Forecast, By End User 12.8.1. Hospitals and Clinics 12.8.2. Diagnostic Laboratories 12.8.3. Other End Users 12.9. Europe Addison’s Disease Drugs Market Value Share Analysis, by Country 12.10. Europe Addison’s Disease Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Addison’s Disease Drugs Market Analysis, by Country 12.12. Germany Addison’s Disease Drugs Market Forecast, By Diagnosis 12.12.1. Laboratory Tests 12.12.2. Image Tests 12.13. Germany Addison’s Disease Drugs Market Forecast, By Treatment 12.13.1. Oral Corticosteroid 12.13.2. Corticosteroid Injections 12.14. Germany Addison’s Disease Drugs Market Forecast, By End User 12.14.1. Hospitals and Clinics 12.14.2. Diagnostic Laboratories 12.14.3. Other End Users 12.15. U.K. Addison’s Disease Drugs Market Forecast, By Diagnosis 12.15.1. Laboratory Tests 12.15.2. Image Tests 12.16. U.K. Addison’s Disease Drugs Market Forecast, By Treatment 12.16.1. Oral Corticosteroid 12.16.2. Corticosteroid Injections 12.17. U.K. Addison’s Disease Drugs Market Forecast, By End User 12.17.1. Hospitals and Clinics 12.17.2. Diagnostic Laboratories 12.17.3. Other End Users 12.18. France Addison’s Disease Drugs Market Forecast, By Diagnosis 12.18.1. Laboratory Tests 12.18.2. Image Tests 12.19. France Addison’s Disease Drugs Market Forecast, By Treatment 12.19.1. Oral Corticosteroid 12.19.2. Corticosteroid Injections 12.20. France Addison’s Disease Drugs Market Forecast, By End User 12.20.1. Hospitals and Clinics 12.20.2. Diagnostic Laboratories 12.20.3. Other End Users 12.21. Italy Addison’s Disease Drugs Market Forecast, By Diagnosis 12.21.1. Laboratory Tests 12.21.2. Image Tests 12.22. Italy Addison’s Disease Drugs Market Forecast, By Treatment 12.22.1. Oral Corticosteroid 12.22.2. Corticosteroid Injections 12.23. Italy Addison’s Disease Drugs Market Forecast, By End User 12.23.1. Hospitals and Clinics 12.23.2. Diagnostic Laboratories 12.23.3. Other End Users 12.24. Spain Addison’s Disease Drugs Market Forecast, By Diagnosis 12.24.1. Laboratory Tests 12.24.2. Image Tests 12.25. Spain Addison’s Disease Drugs Market Forecast, By Treatment 12.25.1. Oral Corticosteroid 12.25.2. Corticosteroid Injections 12.26. Spain Addison’s Disease Drugs Market Forecast, By End User 12.26.1. Hospitals and Clinics 12.26.2. Diagnostic Laboratories 12.26.3. Other End Users 12.27. Rest of Europe Addison’s Disease Drugs Market Forecast, By Diagnosis 12.27.1. Laboratory Tests 12.27.2. Image Tests 12.28. Rest of Europe Addison’s Disease Drugs Market Forecast, By Treatment 12.28.1. Oral Corticosteroid 12.28.2. Corticosteroid Injections 12.29. Rest of Europe Addison’s Disease Drugs Market Forecast, By End User 12.29.1. Hospitals and Clinics 12.29.2. Diagnostic Laboratories 12.29.3. Other End Users 12.30. Europe Addison’s Disease Drugs Market Attractiveness Analysis 12.30.1. By Diagnosis 12.30.2. By Treatment 12.30.3. By End User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Addison’s Disease Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Addison’s Disease Drugs Market Overview 13.3. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 13.4. Asia Pacific Addison’s Disease Drugs Market Forecast, By Diagnosis 13.4.1. Laboratory Tests 13.4.2. Image Tests 13.5. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By Treatment 13.6. Asia Pacific Addison’s Disease Drugs Market Forecast, By Treatment 13.6.1. Oral Corticosteroid 13.6.2. Corticosteroid Injections 13.7. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, By End User 13.8. Asia Pacific Addison’s Disease Drugs Market Forecast, By End User 13.8.1. Hospitals and Clinics 13.8.2. Diagnostic Laboratories 13.8.3. Other End Users 13.9. Asia Pacific Addison’s Disease Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Addison’s Disease Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Addison’s Disease Drugs Market Analysis, by Country 13.12. China Addison’s Disease Drugs Market Forecast, By Diagnosis 13.12.1. Laboratory Tests 13.12.2. Image Tests 13.13. China Addison’s Disease Drugs Market Forecast, By Treatment 13.13.1. Oral Corticosteroid 13.13.2. Corticosteroid Injections 13.14. China Addison’s Disease Drugs Market Forecast, By End User 13.14.1. Hospitals and Clinics 13.14.2. Diagnostic Laboratories 13.14.3. Other End Users 13.15. India Addison’s Disease Drugs Market Forecast, By Diagnosis 13.15.1. Laboratory Tests 13.15.2. Image Tests 13.16. India Addison’s Disease Drugs Market Forecast, By Treatment 13.16.1. Oral Corticosteroid 13.16.2. Corticosteroid Injections 13.17. India Addison’s Disease Drugs Market Forecast, By End User 13.17.1. Hospitals and Clinics 13.17.2. Diagnostic Laboratories 13.17.3. Other End Users 13.18. Japan Addison’s Disease Drugs Market Forecast, By Diagnosis 13.18.1. Laboratory Tests 13.18.2. Image Tests 13.19. Japan Addison’s Disease Drugs Market Forecast, By Treatment 13.19.1. Oral Corticosteroid 13.19.2. Corticosteroid Injections 13.20. Japan Addison’s Disease Drugs Market Forecast, By End User 13.20.1. Hospitals and Clinics 13.20.2. Diagnostic Laboratories 13.20.3. Other End Users 13.21. ASEAN Addison’s Disease Drugs Market Forecast, By Diagnosis 13.21.1. Laboratory Tests 13.21.2. Image Tests 13.22. ASEAN Addison’s Disease Drugs Market Forecast, By Treatment 13.22.1. Oral Corticosteroid 13.22.2. Corticosteroid Injections 13.23. ASEAN Addison’s Disease Drugs Market Forecast, By End User 13.23.1. Hospitals and Clinics 13.23.2. Diagnostic Laboratories 13.23.3. Other End Users 13.24. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By Diagnosis 13.24.1. Laboratory Tests 13.24.2. Image Tests 13.25. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By Treatment 13.25.1. Oral Corticosteroid 13.25.2. Corticosteroid Injections 13.26. Rest of Asia Pacific Addison’s Disease Drugs Market Forecast, By End User 13.26.1. Hospitals and Clinics 13.26.2. Diagnostic Laboratories 13.26.3. Other End Users 13.27. Asia Pacific Addison’s Disease Drugs Market Attractiveness Analysis 13.27.1. By Diagnosis 13.27.2. By Treatment 13.27.3. By End User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Addison’s Disease Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Addison’s Disease Drugs Market Overview 14.3. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 14.4. Middle East & Africa Addison’s Disease Drugs Market Forecast, By Diagnosis 14.4.1. Laboratory Tests 14.4.2. Image Tests 14.5. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By Treatment 14.6. Middle East & Africa Addison’s Disease Drugs Market Forecast, By Treatment 14.6.1. Oral Corticosteroid 14.6.2. Corticosteroid Injections 14.7. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, By End User 14.8. Middle East & Africa Addison’s Disease Drugs Market Forecast, By End User 14.8.1. Hospitals and Clinics 14.8.2. Diagnostic Laboratories 14.8.3. Other End Users 14.9. Middle East & Africa Addison’s Disease Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Addison’s Disease Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Addison’s Disease Drugs Market Analysis, by Country 14.12. GCC Addison’s Disease Drugs Market Forecast, By Diagnosis 14.12.1. Laboratory Tests 14.12.2. Image Tests 14.13. GCC Addison’s Disease Drugs Market Forecast, By Treatment 14.13.1. Oral Corticosteroid 14.13.2. Corticosteroid Injections 14.14. GCC Addison’s Disease Drugs Market Forecast, By End User 14.14.1. Hospitals and Clinics 14.14.2. Diagnostic Laboratories 14.14.3. Other End Users 14.15. South Africa Addison’s Disease Drugs Market Forecast, By Diagnosis 14.15.1. Laboratory Tests 14.15.2. Image Tests 14.16. South Africa Addison’s Disease Drugs Market Forecast, By Treatment 14.16.1. Oral Corticosteroid 14.16.2. Corticosteroid Injections 14.17. South Africa Addison’s Disease Drugs Market Forecast, By End User 14.17.1. Hospitals and Clinics 14.17.2. Diagnostic Laboratories 14.17.3. Other End Users 14.18. Rest of Middle East & Africa Addison’s Disease Drugs Market Forecast, By Diagnosis 14.18.1. Laboratory Tests 14.18.2. Image Tests 14.19. Rest of Middle East & Africa Addison’s Disease Drugs Market Forecast, By Treatment 14.19.1. Oral Corticosteroid 14.19.2. Corticosteroid Injections 14.20. Middle East & Africa Addison’s Disease Drugs Market Forecast, By End User 14.20.1. Hospitals and Clinics 14.20.2. Diagnostic Laboratories 14.20.3. Other End Users 14.21. Middle East & Africa Addison’s Disease Drugs Market Attractiveness Analysis 14.21.1. By Diagnosis 14.21.2. By Treatment 14.21.3. By End User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Addison’s Disease Drugs Market Analysis 15.1. Key Findings 15.2. South America Addison’s Disease Drugs Market Overview 15.3. South America Addison’s Disease Drugs Market Value Share Analysis, By Diagnosis 15.4. South America Addison’s Disease Drugs Market Forecast, By Diagnosis 15.4.1. Laboratory Tests 15.4.2. Image Tests 15.5. South America Addison’s Disease Drugs Market Value Share Analysis, By Treatment 15.6. South America Addison’s Disease Drugs Market Forecast, By Treatment 15.6.1. Oral Corticosteroid 15.6.2. Corticosteroid Injections 15.7. South America Addison’s Disease Drugs Market Value Share Analysis, By End User 15.8. South America Addison’s Disease Drugs Market Forecast, By End User 15.8.1. Hospitals and Clinics 15.8.2. Diagnostic Laboratories 15.8.3. Other End Users 15.9. South America Addison’s Disease Drugs Market Value Share Analysis, by Country 15.10. South America Addison’s Disease Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Addison’s Disease Drugs Market Analysis, by Country 15.12. Brazil Addison’s Disease Drugs Market Forecast, By Diagnosis 15.12.1. Laboratory Tests 15.12.2. Image Tests 15.13. Brazil Addison’s Disease Drugs Market Forecast, By Treatment 15.13.1. Oral Corticosteroid 15.13.2. Corticosteroid Injections 15.14. Brazil Addison’s Disease Drugs Market Forecast, By End User 15.14.1. Hospitals and Clinics 15.14.2. Diagnostic Laboratories 15.14.3. Other End Users 15.15. Mexico Addison’s Disease Drugs Market Forecast, By Diagnosis 15.15.1. Laboratory Tests 15.15.2. Image Tests 15.16. Mexico Addison’s Disease Drugs Market Forecast, By Treatment 15.16.1. Oral Corticosteroid 15.16.2. Corticosteroid Injections 15.17. Mexico Addison’s Disease Drugs Market Forecast, By End User 15.17.1. Hospitals and Clinics 15.17.2. Diagnostic Laboratories 15.17.3. Other End Users 15.18. Rest of South America Addison’s Disease Drugs Market Forecast, By Diagnosis 15.18.1. Laboratory Tests 15.18.2. Image Tests 15.19. Rest of South America Addison’s Disease Drugs Market Forecast, By Treatment 15.19.1. Oral Corticosteroid 15.19.2. Corticosteroid Injections 15.20. Rest of South America Addison’s Disease Drugs Market Forecast, By End User 15.20.1. Hospitals and Clinics 15.20.2. Diagnostic Laboratories 15.20.3. Other End Users 15.21. South America Addison’s Disease Drugs Market Attractiveness Analysis 15.21.1. By Diagnosis 15.21.2. By Treatment 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Bristol-Myers Squibb Company 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Bristol-Myers Squibb Company 16.3.2. Merck & Co. Inc. 16.3.3. Novartis AG 16.3.4. Pfizer Inc. 16.3.5. Takeda Pharmaceutical Company Ltd 16.3.6. Boehringer Ingelheim International GmbH 16.3.7. Shire 16.3.8. Tocris Bioscience 16.3.9. GlaxoSmithKline 16.3.10. Lupin Pharmaceuticals Inc. 16.3.11. Abbott Laboratories 16.3.12. Amgen Limited 16.3.13. Bayer AG 16.3.14. Biogen 16.3.15. Eli Lilly and Company 16.3.16. Diurnal 16.3.17. Bio-Techne 16.3.18. Switzer Life Science 16.3.19. Recipharm 16.3.20. ViroPharma

Addison’s Disease Drugs Market